Loading...

SRPT SAREPTA THERAPEUTICS INC Capital Structure Changes 8-K Filing

SRPT

SRPT

SAREPTA THERAPEUTICS INC

(SRPT)

2025 8-K

Convertible Notes Exchange

CEO Equity Grant

Financial Results Announced

Convertible Notes Exchange

Debt Exchange Agreement

Management Change

Clinical Trials

Reduction in Force

Rights Offerings

Earnings Announcement

Credit Agreement

Financial Results

Collaboration Agreement

Amendment to Incentive Plan

Financial Results

FDA Approval of ELEVIDYS

Annual Meeting Results

External Links:

On December 10, 2025, Sarepta Therapeutics, Inc. finalized an agreement to exchange approximately $291.4 million of existing convertible notes for new notes and cash, with the exchange expected to close by December 18, 2025.

AI Assistant

SAREPTA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.